Skip to main content

Drug Interactions between AccessPak for HIV PEP Basic and orlistat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

orlistat tenofovir

Applies to: orlistat and AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil)

MONITOR: Orlistat may theoretically reduce the gastrointestinal absorption and therapeutic efficacy of antiretroviral agents. The mechanism may involve retention of lipophilic medicines in the gastrointestinal tract or reduced gastrointestinal tract transit time. Data have been reported for efavirenz and lopinavir. Other antiretroviral agents may also be affected.

MANAGEMENT: The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat. Patients who take antiretroviral medications should be advised to consult their physician before using the non-prescription brand of orlistat.

References (1)
  1. MHRA. Medicines and Healthcare Products Regulatory Agency (2014) Orlistat: theoretical interaction with antiretroviral HIV medicines. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392868
Moderate

orlistat emtricitabine

Applies to: orlistat and AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil)

MONITOR: Orlistat may theoretically reduce the gastrointestinal absorption and therapeutic efficacy of antiretroviral agents. The mechanism may involve retention of lipophilic medicines in the gastrointestinal tract or reduced gastrointestinal tract transit time. Data have been reported for efavirenz and lopinavir. Other antiretroviral agents may also be affected.

MANAGEMENT: The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat. Patients who take antiretroviral medications should be advised to consult their physician before using the non-prescription brand of orlistat.

References (1)
  1. MHRA. Medicines and Healthcare Products Regulatory Agency (2014) Orlistat: theoretical interaction with antiretroviral HIV medicines. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392868

Drug and food interactions

Minor

tenofovir food

Applies to: AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil)

Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.

References (1)
  1. (2001) "Product Information. Viread (tenofovir)." Gilead Sciences

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer